Oriana Ciani, PhD
About
Research
Publications
2024
Surrogate endpoints in randomised trials of physiotherapy interventions: the SPIRIT and CONSORT extension checklists for better reporting
Faria C, Polese J, Manyara A, Taylor R, Ciani O, Scianni A. Surrogate endpoints in randomised trials of physiotherapy interventions: the SPIRIT and CONSORT extension checklists for better reporting. Journal Of Physiotherapy 2024 PMID: 39690082, DOI: 10.1016/j.jphys.2024.11.013.Peer-Reviewed Original ResearchValue Attribution for Combination Treatments: Two Potential Solutions for an Insoluble Problem
Ciani O, Jommi C. Value Attribution for Combination Treatments: Two Potential Solutions for an Insoluble Problem. Value In Health 2024 PMID: 39581497, DOI: 10.1016/j.jval.2024.11.002.Peer-Reviewed Original ResearchCorrection: Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT)
Bertolaccini L, CIani O, Lucchi M, Zaraca F, Bertani A, Crisci R, Spaggiari L, Group L. Correction: Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT). JMIR Research Protocols 2024, 13: e67629. PMID: 39471369, PMCID: PMC11558210, DOI: 10.2196/67629.Peer-Reviewed Original ResearchAssessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
Generali D, Rocca A, Strina C, Milani M, Fiorino E, Cervoni V, Azzini C, Saracino A, Ciliberto I, Ziglioli N, Alberio M, Giudici F, Dester M, Ciani O, Fornaro G, Aguggini S, Dreezen C, Pronin D, Ende S. Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients. Heliyon 2024, 10: e39485. PMID: 39553665, PMCID: PMC11564935, DOI: 10.1016/j.heliyon.2024.e39485.Peer-Reviewed Original ResearchLow-risk tumorsHigh-risk tumorsRisk tumorsOverall survivalBreast cancerFollow-upPrognostic performanceHigh-risk BC patientsIntermediate-risk breast cancerLong-term prognostic abilitySingle-center prospective cohort studyPathologic tumor characteristicsProgesterone receptor-positiveSingle-center prospective cohortMedian follow-upBreast cancer patientsGenomic riskProspective cohort studyCox regression modelsPersonalize treatment choicesNodal statusReceptor statusReceptor-positiveTumor characteristicsTumor sizeDesign and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification
Ardito V, Ciani O, Drummond M. Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification. PharmacoEconomics 2024, 1-25. PMID: 39405025, DOI: 10.1007/s40273-024-01435-2.Peer-Reviewed Original ResearchHealth technologiesPreferred Reporting ItemsGroups of keywordsMethodsA Preferred Reporting ItemsScoping reviewDecision makersReporting ItemsIndependent reviewersOutcome componentsSystematic reviewPayment schemeNarrative formatSchemeComprehensive categorizationCollection requirementsProblem of affordabilityHealthClassificationFeatures of pricingOutcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT)
Bertolaccini L, Ciani O, Lucchi M, Zaraca F, Bertani A, Crisci R, Spaggiari L, Group L. Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT). JMIR Research Protocols 2024, 13: e57183. PMID: 39378423, PMCID: PMC11496920, DOI: 10.2196/57183.Peer-Reviewed Original ResearchConceptsLocally advanced lung cancerNon-small cell lung cancerOutcomes of patientsAdvanced lung cancerLung cancerWeb-based registryINTERNATIONAL REGISTERED REPORT IDENTIFIERObservational studySecondary objectivesSuboptimal response ratesEvolving treatment paradigmCell lung cancerLung cancer managementTraditional open surgeryInfluence treatment strategiesStudy's secondary objectivePatient-reported outcomesNational benchmarksOpen surgeryProcess of care indicatorsRisk-adjusted outcomesTreatment paradigmNSCLC treatmentCancer managementFollow-upMA14.13 Analysis of Lung Cancer-Specific Patient-Reported Outcome Measures (PROMs): Results from the PRO4All Project
Servetto A, Malandrini F, Meregaglia M, Valsecchi A, Bennati C, Giovanardi F, Pinto C, Di Maio M, Ciani O. MA14.13 Analysis of Lung Cancer-Specific Patient-Reported Outcome Measures (PROMs): Results from the PRO4All Project. Journal Of Thoracic Oncology 2024, 19: s115-s116. DOI: 10.1016/j.jtho.2024.09.207.Peer-Reviewed Original ResearchBreast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: Results from the PRO4All project
Valsecchi A, Giovanardi F, Malandrini F, Meregaglia M, Servetto A, Bennati C, Pinto C, Di Maio M, Ciani O. Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: Results from the PRO4All project. The Breast 2024, 78: 103817. PMID: 39362075, PMCID: PMC11651043, DOI: 10.1016/j.breast.2024.103817.Peer-Reviewed Original ResearchPatient-reported outcome measuresMinimum clinically important differencePatient-reported outcomesOutcome measuresBreast cancerRecall periodInclusion of patient-reported outcomesDelivery of carePatient-centered approachClinically important differenceClinical researchPhysical functionOutcome domainsOutcome classificationImportant differenceSelf-reportOncology clinical trialsQuestionnaireEvaluation of treatmentQuestionnaire descriptionsPublished reviewsClinical practiceOncologyItemsBC patientsArtificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial
Borsoi L, Listorti E, Ciani O. Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial. PharmacoEconomics - Open 2024, 8: 945-959. PMID: 39264499, PMCID: PMC11499581, DOI: 10.1007/s41669-024-00519-1.Peer-Reviewed Original ResearchBreast cancer patientsBackgroundShared decision-makingBreast cancer careCloud-based approachPatient decision aidsMultidimensional evaluationCloud-based platformReduce decision regretCost-utility analysisCancer patientsCancer carePatient-level dataHealthcare professionalsArtificial-intelligenceMobile applicationsPersonalized contentDecision regretCountry-specific unit costsFocus groupsLocoregional treatmentPatient questionnaireDecision aidPatient valuationsReal-world settingsWeb platformSurrogate End Points in Trials—SPIRIT and CONSORT Extensions
Taylor R, Manyara A, Ross J, Ciani O. Surrogate End Points in Trials—SPIRIT and CONSORT Extensions. JAMA 2024, 332: 1340-1342. PMID: 39102315, DOI: 10.1001/jama.2024.15219.Peer-Reviewed Original Research
Get In Touch
Contacts
Mailing Address
Yale School of Public Health
350 George Street, Yale School of Public Health
New Haven, CT 06511
United States